Answers are grounded in this paper and cite their sources.
Single-domain antibodies (sdAbs) are emerging scaffolds for antibody-drug conjugates (ADCs) and radioconjugates (RCs). Their small size, modularity, and tunable pharmacokinetics enable alignment of binding, payload, and tumor exposure. This review examines synthetic sdAb library construction, engineering strategies, conjugation chemistry, payload selection, and alignment of target expression with pharmacokinetics and tumor delivery. Evidence from the literature indicates that stability-engineered scaffolds and rationally curated diversity can improve solubility, aggregation resistance, and compatibility with site-specific conjugation. Multivalent, multispecific, and half-life-extended formats broaden options. Future progress will depend on integrating molecular design with target biology to optimize efficacy and safety across payloads and radionuclides.
No takes yet. Share an insight, caveat, or question.
Puthenveetil et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: